A patient who is receiving an immune suppressant has been admitted to the unit. What would be a priority action by the nurse?

Correct Answer: C

Rationale: The correct answer is C because protecting the patient from exposure to infection is a priority for a patient receiving immune suppressants. Immune suppressants weaken the body's immune system, making the patient more vulnerable to infections. This action helps prevent complications and promotes patient safety. Monitoring nutritional status (A) is important but not as urgent as preventing infections. Providing patient teaching (B) and support for adverse effects (D) are important but secondary to preventing infections in a patient on immune suppressants.

Correct Answer: A

Rationale: The correct answer is A because immune suppressants block the normal effects of the immune system in order to prevent rejection of the transplanted organ. By suppressing the immune response, the body is less likely to attack and reject the new organ. Choice B is incorrect because immune suppressants do the opposite of stimulating the immune system - they actually suppress it. Choice C is incorrect because immune suppressants do not work with corticosteroids to enhance healing. They work independently to suppress the immune response. Choice D is incorrect because immune suppressants do not work with corticosteroids to promote suppressor cells. Suppressors cells play a different role in the immune system compared to immune suppressants.

Correct Answer: C

Rationale: The correct answer is C: Interferon alfa 2b. Interferon alfa 2b is commonly used in the treatment of Kaposi's sarcoma. It has shown efficacy in inhibiting the growth of tumor cells and boosting the immune system. Interferon beta1a (A) is used for multiple sclerosis, not Kaposi's sarcoma. Interferon gamma 1b (B) is used for chronic granulomatous disease, not Kaposi's sarcoma. Peginterferon alfa 2b (D) is used for hepatitis C, not Kaposi's sarcoma. Hence, choice C is the most appropriate for this patient.

Correct Answer: A

Rationale: The correct answer is A: Palivizumab. Palivizumab is used to prevent RSV in high-risk children by targeting the RSV F protein, reducing the severity of infection. Natalizumab (B) is used for multiple sclerosis, Belimumab (C) is for systemic lupus erythematosus, and Eculizumab (D) is for atypical hemolytic uremic syndrome, making them incorrect choices for preventing RSV.

Correct Answer: C

Rationale: Interleukins are signaling proteins that mediate communication between leukocytes to regulate immune responses. Choice C accurately describes interleukins' function in stimulating immunity through leukocyte interactions. Choice A is incorrect because interleukins are not produced in response to viral invasion specifically. Choice B is incorrect as interleukins generally regulate and amplify inflammatory responses instead of blocking them. Choice D is incorrect because while interleukins do bind to specific receptors, they are involved in a broader range of immune responses beyond very specific situations.